Straight Path Crossed: Speculative Short To M&A Darling, A Look Back At StraightPath Communications Journey
Kerrisdale Capital Short Thesis On Sage Therapeutics: Lead Drug 'Likely To Fail' In Phase 3
Straight Path Crossed: Speculative Short To M&A Darling, A Look Back At StraightPath Communications Journey
Kerrisdale Capital Short Thesis On Sage Therapeutics: Lead Drug 'Likely To Fail' In Phase 3
Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'
Shares Of Five Below Drop Following Negative Report By Kerrisdale